Malignant gliomas are considered to be among the deadliest of human cancers. Although we have gained detailed knowledge of a number of genetic pathways mutated in gliomas, recent studies suggest additional mutations play significant role in the phenotype and resistance of this disease. The overall goal of the Neuropathology Core is to provide expert, high throughput, and highly integrated tissue based analysis of human and mouse gliomas the P01. The research of each project is heavily based upon the in vtvo biology of human and mouse gliomas, and as such, the Neuropathology Core services are essential for the success of the P01. In addition, the Core strives to improve the services it delivers through the development of emerging tissue technologies that will reduce the difficulties each project encounters in studying increasingly limited tissue resources. Moreover, the centralized nature of the Core will foster intellectual resource sharing and allow investigators to compare and interpret their findings within the spectrum of research performed across all the projects. The Neuropathology Core has three specific aims: 1) to provide pathologic analysis and interpretation of human and mouse gliomas. 2) to characterize human and mouse gliomas using molecular pathology tools. 3) to develop and implement novel technologies for cellular and molecular characterization of human and mouse gliomas. The Core has the requisite neuropathologic expertise, sophisticated resources, and experienced staff to carry out these aims and ensure that the P01 meets its overall goals of discovery of targets for therapy in malignant glioma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA095616-09
Application #
8234814
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2011-12-31
Budget Start
2011-03-01
Budget End
2012-02-29
Support Year
9
Fiscal Year
2011
Total Cost
$152,507
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Reardon, Colin; Murray, Kaitlin; Lomax, Alan E (2018) Neuroimmune Communication in Health and Disease. Physiol Rev 98:2287-2316
Roncali, Emilie; Stockhoff, Mariele; Cherry, Simon R (2017) An integrated model of scintillator-reflector properties for advanced simulations of optical transport. Phys Med Biol 62:4811-4830
Nanavaty, Vishal; Sandhu, Ranjodh; Jehi, Sanaa E et al. (2017) Trypanosoma brucei RAP1 maintains telomere and subtelomere integrity by suppressing TERRA and telomeric RNA:DNA hybrids. Nucleic Acids Res 45:5785-5796
Liu, Rui; Yang, Guang; Zhou, Meng-Hua et al. (2016) Flotillin-1 downregulates K(+) current by directly coupling with Kv2.1 subunit. Protein Cell 7:455-60
Schrager-Lavelle, Amanda; Herrera, Leslie A; Maloof, Julin N (2016) Tomato phyE Is Required for Shade Avoidance in the Absence of phyB1 and phyB2. Front Plant Sci 7:1275
Hu, Baoli; Wang, Qianghu; Wang, Y Alan et al. (2016) Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell 167:1281-1295.e18
Poornima, Gopalakrishna; Shah, Shanaya; Vignesh, Venkadasubramanian et al. (2016) Arginine methylation promotes translation repression activity of eIF4G-binding protein, Scd6. Nucleic Acids Res 44:9358-9368
Frost, Bess; Bardai, Farah H; Feany, Mel B (2016) Lamin Dysfunction Mediates Neurodegeneration in Tauopathies. Curr Biol 26:129-36
Leonard, Paul G; Satani, Nikunj; Maxwell, David et al. (2016) SF2312 is a natural phosphonate inhibitor of enolase. Nat Chem Biol 12:1053-1058
Hiu, Takeshi; Farzampour, Zoya; Paz, Jeanne T et al. (2016) Enhanced phasic GABA inhibition during the repair phase of stroke: a novel therapeutic target. Brain 139:468-80

Showing the most recent 10 out of 146 publications